The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment R Tarawneh, DM Holtzman Cold Spring Harbor perspectives in medicine 2 (5), a006148, 2012 | 557 | 2012 |
ISTH guidelines for treatment of thrombotic thrombocytopenic purpura XL Zheng, SK Vesely, SR Cataland, P Coppo, B Geldziler, A Iorio, ... Journal of Thrombosis and Haemostasis 18 (10), 2496-2502, 2020 | 348 | 2020 |
ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura XL Zheng, SK Vesely, SR Cataland, P Coppo, B Geldziler, A Iorio, ... Journal of Thrombosis and Haemostasis 18 (10), 2486-2495, 2020 | 274 | 2020 |
Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer disease R Tarawneh, G D’Angelo, D Crimmins, E Herries, T Griest, AM Fagan, ... JAMA neurology 73 (5), 561-571, 2016 | 225 | 2016 |
Visinin‐like protein‐1: diagnostic and prognostic biomarker in Alzheimer disease R Tarawneh, G D'Angelo, E Macy, C Xiong, D Carter, NJ Cairns, ... Annals of neurology 70 (2), 274-285, 2011 | 196 | 2011 |
CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease R Tarawneh, JM Lee, JH Ladenson, JC Morris, DM Holtzman Neurology 78 (10), 709-719, 2012 | 119 | 2012 |
Cerebrospinal fluid markers of neurodegeneration and rates of brain atrophy in early Alzheimer disease R Tarawneh, D Head, S Allison, V Buckles, AM Fagan, JH Ladenson, ... JAMA neurology 72 (6), 656-665, 2015 | 106 | 2015 |
Biomarkers in translational research of Alzheimer’s disease R Tarawneh, DM Holtzman Neuropharmacology 59 (4-5), 310-322, 2010 | 88 | 2010 |
Anatomically interpretable deep learning of brain age captures domain-specific cognitive impairment C Yin, P Imms, M Cheng, A Amgalan, NF Chowdhury, RJ Massett, ... Proceedings of the National Academy of Sciences 120 (2), e2214634120, 2023 | 65 | 2023 |
Potential future neuroprotective therapies for neurodegenerative disorders and stroke R Tarawneh, JE Galvin Clinics in Geriatric Medicine 26 (1), 125-147, 2010 | 65 | 2010 |
Distinguishing Lewy body dementias from Alzheimer’s disease R Tarawneh, JE Galvin Expert review of neurotherapeutics 7 (11), 1499-1516, 2007 | 62 | 2007 |
The gut microbiome and Alzheimer’s disease: Complex and bidirectional interactions R Tarawneh, E Penhos Neuroscience & Biobehavioral Reviews 141, 104814, 2022 | 55 | 2022 |
Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura XL Zheng, SK Vesely, SR Cataland, P Coppo, B Geldziler, A Iorio, ... Journal of Thrombosis and Haemostasis 18 (10), 2503-2512, 2020 | 53 | 2020 |
Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention R Tarawneh, DM Holtzman CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS …, 2009 | 46 | 2009 |
Agitation and impulsivity in mid and late life as possible risk markers for incident dementia DR Bateman, S Gill, S Hu, ED Foster, MT Ruthirakuhan, AF Sellek, ... Alzheimer's & Dementia: Translational Research & Clinical Interventions 6 (1 …, 2020 | 38 | 2020 |
Biomarkers: our path towards a cure for Alzheimer disease R Tarawneh Biomarker insights 15, 1177271920976367, 2020 | 35 | 2020 |
Etiology of white matter hyperintensities in autosomal dominant and sporadic Alzheimer disease Z Shirzadi, SA Schultz, WYW Yau, N Joseph-Mathurin, CD Fitzpatrick, ... JAMA neurology 80 (12), 1353-1363, 2023 | 30 | 2023 |
Clinical efficacy, drug safety, and surrogate endpoints: has aducanumab met all of its expectations? LA Hershey, R Tarawneh Neurology 97 (11), 517-518, 2021 | 25 | 2021 |
Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40 Y Deming, K Black, D Carrell, Y Cai, JL Del-Aguila, MV Fernandez, ... BMC neurology 16, 1-8, 2016 | 18 | 2016 |
Vascular endothelial‐cadherin as a marker of endothelial injury in preclinical Alzheimer disease R Tarawneh, RS Kasper, J Sanford, CL Phuah, J Hassenstab, ... Annals of clinical and translational neurology 9 (12), 1926-1940, 2022 | 15 | 2022 |